Lacie sells ARIA 6.74: Baxalta already has six oncology product candidates for as many as 16 different indications in its pipeline.

Baxalta extended a takeover bid to Ariad valued at approximately $2 billion on August 28. The bid was rejected soon after as Ariad wasn't happy with the valuation. Given the scenario, no chances on resumption of dialogue stand, although no confirmation has not been issued by either company yet. It is also being reported that Baxalta doesn't seem happy to hear that Ariad could attract a takeover by a party of its own investors. Ariad Pharmaceuticals CFO Edward M. Ariad's management, on the other hand, may think otherwise, evinced by their statements at various investor conferences, leading them to demand a premium that's ultimately too rich for Baxalta.


Isabelle:
Initially, Iclusig was approved as a treatment for  chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia in patients who had failed to respond to at least one other therapy.

Jenice:
Investors don't want to make any strong commitments to the upside or downside right now.

Florine:
There are still some good stories out there, but not as many.

Sophie:
I see more threats to bull market catalysts now than I've seen in a while.

Alesia:
There aren't many win-win situations in the stock market.

Elsie:
There are no limits to how many times you can do this.

Davida:
Here again, though, you still have the stock and will be free to sell another call, take in more cash, and further offset any losses.

Deane:
And you are free to sell another call, taking in more money.

Lizzette:
If the stock moves sideways, you keep the covered call money and the stock.

Muoi:
If the stock rallies past the price at which you agreed to sell, you keep the money from the covered call plus the profit from the stock.

Ariad Pharmaceuticals (NASDAQ:ARIA)
//stockhand.net/us/?q=nasdaq%3Aaria&id=367702